The FDA GMP regulations in 21CFR211.25(a) require the performance of GMP training “…on a continuing basis and with sufficient frequency to assure that employees remain familiar with CGMP requirements…” Pharmaceutical industry standard provides repeat GMP training to all employees at an annual frequency, at minimum, to comply with this GMP requirement.
This presentation on “FDA Enforcement and Compliance Trends” fulfills the FDA requirement for continuing CGMP training with an analysis of FDA-483 and FDA warning letter citations issued in FDA Fiscal Year (FY) 2020, to identify and review the major GMP compliance deficiencies, trends and issues. The presentation includes the following topics:
The attendee will gain knowledge of the latest FDA expectations and interpretations for GMP compliance to fulfill the 21CFR211.25(a) regulation to remain familiar with the GMP requirements. Attendees with responsibilities for GMP compliance and product quality will use their learnings to assess their companies’ GMP compliance profile and to implement corrective actions, if necessary, to avoid FDA regulatory actions.
This presentation is targeted for professionals and management who have direct or indirect responsibilities for supervising or assuring GMP compliance and product quality; for example, quality assurance, GMP compliance auditing, quality control laboratories and manufacturing. Professionals for raw material procurement and contactor services would benefit from the information related to the FDA’s increased compliance focus for suppliers and contractors, and the FDA’s enforcement of its import alert program.
This course is available as an In-House Training course. Let us know if you wish to customize a course or if you are a large group with the same requirements.
Leading specialist with long experience of training are guiding you through regulations, guidelines, interpretations, requirements and applications.
For your best experience are we using cookies on this website.